Literature DB >> 3476144

Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML).

A N Stark, J Thorogood, C Head, B E Roberts, C S Scott.   

Abstract

Ninety-seven cases of chronic myelomonocytic leukaemia (CMML) were examined retrospectively for survival and possible prognostic factors including age, total white cell count, peripheral blood and bone marrow monocyte counts, % double esterase (DE) positive cells in bone marrow and serum lysozyme. Age, absolute monocyte counts and serum lysozyme proved to be significant independent prognostic indicators but Cox model analyses showed serum lysozyme to be the most important factor whether taken as a continuous or discrete (two groups) variable. Twelve cases of second malignancy were found, including 2 cases of multiple myeloma, but this was not significantly greater than expected when compared with an age and sex matched group.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3476144      PMCID: PMC2001685          DOI: 10.1038/bjc.1987.154

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Double esterase positive cells.

Authors:  C S Scott; A Cahill; M Morgan; B E Roberts
Journal:  Br J Haematol       Date:  1984-12       Impact factor: 6.998

2.  Cytochemical and immunological characteristics of acute monocytic leukaemia.

Authors:  D W Milligan; B E Roberts; H J Limbert; S Jalihal; C S Scott
Journal:  Br J Haematol       Date:  1984-11       Impact factor: 6.998

3.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

4.  Intracellular lactic dehydrogenase and phosphohexose isomerase activity in leukaemia and malignant lymphoma.

Authors:  A D Ho; W Fiehn; W Hunstein
Journal:  Br J Haematol       Date:  1982-04       Impact factor: 6.998

5.  Pancytopenia with hypercellular bone marrow--a possible paraneoplastic syndrome in carcinoma of the lung: a report of three cases.

Authors:  I Raz; E Shinar; A Polliack
Journal:  Am J Hematol       Date:  1984-05       Impact factor: 10.047

6.  Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases.

Authors:  P Solal-Celigny; B Desaint; A Herrera; C Chastang; M Amar; M Vroclans; N Brousse; F Mancilla; M Renoux; J F Bernard
Journal:  Blood       Date:  1984-03       Impact factor: 22.113

7.  Esterase cytochemistry in primary myelodysplastic syndromes and megaloblastic anaemias: demonstration of abnormal staining patterns associated with dysmyelopoiesis.

Authors:  C S Scott; A Cahill; A G Bynoe; M J Ainley; D Hough; B E Roberts
Journal:  Br J Haematol       Date:  1983-11       Impact factor: 6.998

8.  Coexistent myelodysplasia and plasma cell neoplasia.

Authors:  G J Mufti; T J Hamblin; G P Clein; C Race
Journal:  Br J Haematol       Date:  1983-05       Impact factor: 6.998

9.  Chronic myelomonocytic leukemia in childhood.

Authors:  W J Thomas; R B North; D G Poplack; R B Slease; B Duval-Arnould
Journal:  Am J Hematol       Date:  1981       Impact factor: 10.047

Review 10.  Enzymes, isozymes, and enzyme variants in the diagnosis of cancer. A short review.

Authors:  M Stefanini
Journal:  Cancer       Date:  1985-05-01       Impact factor: 6.860

View more
  3 in total

1.  [Clinical course, morphology and prognosis of chronic myelomonocytic leukemia].

Authors:  U Germing; C Strupp; G Meckenstock; A Giagounidis; H Minning; C Aul
Journal:  Med Klin (Munich)       Date:  1999-09-15

2.  A forgotten cause of kidney injury in chronic myelomonocytic leukemia.

Authors:  Tejas V Patel; Helmut G Rennke; J Mark Sloan; Daniel J DeAngelo; David M Charytan
Journal:  Am J Kidney Dis       Date:  2009-01-29       Impact factor: 8.860

Review 3.  Models of Prognostication in Chronic Myelomonocytic Leukemia.

Authors:  Francesco Onida
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.